11 Best Strong Buy Healthcare Stocks to Invest In
On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks.
Boston Scientific Corp (BSX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 11,249,204 | $1,072,611,602 | +27% | 0.59% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 11,035,628 | $1,052,247,130 | +32% | 0.62% |
| 3. | Millennium Management Israel Englander | 11,264,790 | $1,026,422,727 | +33% | 0.43% |
| 4. | Fisher Asset Management Ken Fisher | 9,138,216 | $871,328,966 | +9% | 0.3% |
| 5. | Farallon Capital Thomas Steyer | 7,439,564 | $709,362,427 | +57% | 3.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.29 | 50 | $4,514.60 | 148,168 | 2024-12-03 | Filing | |
| $41.98 | 25,000 | $1,049,450.00 | 25,000 | 2021-11-15 | Filing | |
| $27.50 | 13 | $357.50 | 32,337 | 2017-09-01 | Filing | |
| $27.80 | 30 | $834.00 | 32,324 | 2017-06-16 | Filing | |
| $25.52 | 29 | $740.08 | 32,294 | 2017-04-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $93.49 | 159,701 | $14,930,526.34 | 1,411,735 | 2026-02-02 | Filing | |
| $94.06 | 1,200 | $112,868.04 | 1,571,436 | 2026-02-02 | Filing | |
| $101.55 | 17,313 | $1,758,188.82 | 23,600 | 2025-12-01 | Filing | |
| $98.28 | 12,891 | $1,266,977.75 | 24,134 | 2025-11-06 | Filing | |
| $99.14 | 29,472 | $2,921,895.34 | 178,342 | 2025-11-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 139,685,997 | $13,319,059,814 | 0.19% | |
| 2. | 135,987,245 | $12,966,383,785 | 0.22% | |
| 3. | 97,386,941 | $9,285,844,832 | 0.47% | |
| 4. | 65,846,059 | $6,278,421,726 | 0.21% | |
| 5. | 32,383,765 | $3,073,439,808 | 0.19% |
News See All
Here is Why Boston Scientific Corporation (BSX) is Highly Favored by Hedge Funds
On February 17, the price target on Boston Scientific Corporation (NYSE:BSX) was reduced from $112 to $109 by Canaccord Genuity analyst William Plovanic.
10 Best Healthcare Equipment Stocks to Buy According to Hedge Funds
The Healthcare Equipment segment is one of the areas across the broader healthcare landscape that carries immense innovation prospects and also offers a defensive play.
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to invest in.
10 Best Medical Technology Stocks to Invest In
Medical technology, or MedTech, companies ensure that the broader healthcare industry has the tools needed to diagnose, treat, monitor, or prevent medical conditions.
Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback
On February 5, Truist lowered its price objective on Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The firm maintained a Buy rating on the stock.
13 Best Long Term Low Risk Stocks to Buy Now
As markets continue to shift, many investors are starting to slow down and think in longer time frames.
Boston Scientific Corporation (NYSE:BSX) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Boston Scientific (BSX) Garnering Bullish Views Amid Penumbra Acquisition
The analyst attributed his rating to the company’s strategic acquisition of Penumbra (PEN), which he believes will bolster the business’s durability.
12 Best Medical Devices Stocks to Invest In According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
Hedge Fund Resource Center